NASDAQ : KLRS
Kalaris Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 48.32M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 14.89M | 15.40M | 6.69M | 1.76M | 2.24M |
| Research & Development | 32.87M | 30.75M | 45.04M | 11.71M | 11.76M |
| Operating Expenses | 47.76M | 46.15M | 51.73M | 13.46M | 14.01M |
| Operating Income | -47.76M | -46.15M | -51.73M | -13.46M | -14.01M |
| Interest Expense | -1.63M | -40.72M | -1.58M | -1.03M | |
| Other Non Operating Income (Expenses) | 3.50M | 4.34M | 23.28M | 344.00K | 747.00K |
| EBT Excluding Unusual Items | -44.26M | -43.44M | -69.17M | -14.70M | -14.29M |
| Other Unusual Items | -1.20M | ||||
| Pretax Income | -44.26M | -43.44M | -69.17M | -14.70M | -15.48M |
| Net Income | -44.26M | -43.44M | -69.17M | -14.70M | -15.48M |
| Net Income to Common | -44.26M | -43.44M | -69.17M | -14.70M | -15.48M |
| Shares Outstanding (Basic) | 21.44M | 15.27M | 1.34M | 6.07M | 4.44M |
| Shares Outstanding (Diluted) | 21.44M | 15.27M | 1.34M | 6.07M | 4.44M |
| EPS (Basic) | -2.06 | -2.85 | -51.77 | -2.42 | -3.48 |
| EPS (Diluted) | -2.06 | -2.85 | -51.77 | -2.42 | -3.48 |
| Free Cash Flow | -41.22M | -38.57M | -20.67M | -14.13M | -9.78M |
| Free Cash Flow Per Share | -1.92 | -2.53 | -15.47 | -2.33 | -2.20 |
| EBITDA | -46.14M | ||||
| D&A For EBITDA | 13.00K | ||||
| EBIT | -47.76M | -46.15M | -51.73M | -13.46M | -14.01M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 43.17M | 98.05M | 1.64M | 3.17M | 3.06M |
| Short-Term Investments | 50.37M | 19.93M | |||
| Cash & Short-Term Investments | 93.54M | 117.98M | 1.64M | 3.17M | 3.06M |
| Prepaid Expenses | 1.87M | 827.00K | 967.00K | 164.00K | 840.00K |
| Total Current Assets | 95.92M | 118.81M | 2.61M | 3.33M | 3.90M |
| Property, Plant & Equipment | 1.39M | 1.48M | |||
| Long-Term Deferred Charges | 3.15M | ||||
| Other Long-Term Assets | 2.23M | 1.45M | 410.00K | ||
| Total Assets | 99.54M | 121.74M | 6.16M | 3.33M | 3.90M |
| Accounts Payable | 1.12M | 1.28M | 1.56M | 2.36M | 2.75M |
| Accrued Expenses | 7.27M | 8.12M | 2.15M | 1.00M | 2.52M |
| Short-Term Debt | 19.91M | ||||
| Current Portion of Leases | 347.00K | 316.00K | |||
| Other Current Liabilities | 1.09M | 579.00K | 420.00K | ||
| Total Current Liabilities | 8.74M | 9.71M | 24.70M | 3.94M | 5.69M |
| Long-Term Debt | 3.25M | ||||
| Long-Term Leases | 1.05M | 1.13M | |||
| Other Long-Term Liabilities | 32.08M | 32.08M | 32.08M | 262.00K | |
| Total Liabilities | 41.87M | 42.92M | 56.78M | 3.94M | 9.21M |
| Common Stock | 2.00K | 2.00K | |||
| Additional Paid-In Capital | 240.11M | 238.81M | 19.95M | 2.38M | 2.42M |
| Retained Earnings | -182.37M | -160.00M | -116.56M | -47.39M | -32.70M |
| Comprehensive Income & Other | -73.00K | 6.00K | |||
| Total Common Equity | 57.67M | 78.81M | -96.62M | -45.02M | -30.27M |
| Shareholders' Equity | 57.67M | 78.81M | -50.62M | -609.00K | -5.31M |
| Total Liabilities & Equity | 99.54M | 121.74M | 6.16M | 3.33M | 3.90M |
| Total Debt | 1.40M | 1.45M | 19.91M | 3.25M | |
| Net Cash (Debt) | 92.14M | 116.53M | -18.27M | 3.17M | -194.00K |
| Net Cash Per Share | 4.30 | 7.63 | -13.67 | 0.52 | -0.04 |
| Filing Date Shares Outstanding | 23.80M | 22.93M | 18.70M | 6.76M | 4.44M |
| Total Common Shares Outstanding | 23.80M | 22.90M | 6.73M | 6.76M | 4.44M |
| Working Capital | 87.18M | 109.09M | -22.10M | -609.00K | -1.79M |
| Book Value Per Share | 2.42 | 3.44 | -14.36 | -6.66 | -6.81 |
| Tangible Book Value | 57.67M | 78.81M | -96.62M | -45.02M | -30.27M |
| Tangible Book Value Per Share | 2.42 | 3.44 | -14.36 | -6.66 | -6.81 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -44.26M | -43.44M | -69.17M | -14.70M | -15.48M |
| Depreciation & Amortization | 33.00K | 13.00K | |||
| Other Amortization | 186.00K | 38.02M | 892.00K | 1.99M | |
| Asset Writedown & Restructuring Costs | 163.00K | ||||
| Loss (Gain) From Sale of Investments | -733.00K | -399.00K | |||
| Stock-Based Compensation | 2.19M | 1.94M | 895.00K | 148.00K | 271.00K |
| Other Operating Activities | 138.00K | -98.00K | 11.71M | 619.00K | -114.00K |
| Change in Accounts Payable | -2.56M | -88.00K | -1.03M | -402.00K | 1.83M |
| Change in Other Net Operating Assets | 4.17M | 3.52M | -1.10M | -690.00K | 1.57M |
| Operating Cash Flow | -41.02M | -38.37M | -20.67M | -14.13M | -9.78M |
| Capital Expenditures | -200.00K | -200.00K | |||
| Investment in Securities | -49.70M | -19.52M | |||
| Investing Cash Flow | -49.90M | -19.72M | |||
| Short-Term Debt Issued | 7.50M | 19.97M | |||
| Long-Term Debt Issued | 6.00M | 4.30M | |||
| Total Debt Issued | 7.50M | 19.97M | 6.00M | 4.30M | |
| Net Debt Issued (Repaid) | 7.50M | 19.97M | 6.00M | 4.30M | |
| Issuance of Common Stock | 42.08M | 42.00M | 3.00K | 5.00K | |
| Other Financing Activities | 3.58M | 105.51M | -2.42M | ||
| Financing Cash Flow | 45.67M | 155.01M | 19.14M | 14.24M | 12.78M |
| Net Cash Flow | -45.25M | 96.91M | -1.53M | 110.00K | 3.00M |
| Free Cash Flow | -41.22M | -38.57M | -20.67M | -14.13M | -9.78M |
| Free Cash Flow Per Share | -1.92 | -2.53 | -15.47 | -2.33 | -2.20 |
| Levered Free Cash Flow | -26.24M | -23.19M | -18.82M | -9.43M | |
| Unlevered Free Cash Flow | -26.24M | -22.36M | -31.39M | -9.34M | |
| Change in Working Capital | 1.61M | 3.43M | -2.12M | -1.09M | 3.40M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 47.61M | 157.85M | |||
| Enterprise Value | -44.53M | 82.39M | |||
| Last Close Price | 2.03 | 8.44 | |||
| PB Ratio | 0.84 | 2.00 | |||
| P/TBV Ratio | 0.83 | 2.00 | |||
| Debt / Equity Ratio | 0.02 | 0.02 | -0.39 | -0.61 | |
| Net Debt / Equity Ratio | -1.60 | -1.48 | -0.36 | 5.20 | -0.04 |
| Net Debt / EBITDA Ratio | 2.53 | ||||
| Net Debt / FCF Ratio | 2.23 | 3.02 | -0.88 | 0.22 | -0.02 |
| Quick Ratio | 10.71 | 12.15 | 0.07 | 0.80 | 0.54 |
| Current Ratio | 10.98 | 12.23 | 0.10 | 0.85 | 0.69 |
| Return on Equity (ROE) | -79.91% | -308.10% | |||
| Return on Assets (ROA) | -31.03% | -45.11% | -681.04% | -232.72% | |
| Return on Capital Employed (ROCE) | -52.60% | -41.20% | 279.00% | 2,210.80% | 781.60% |
| Earnings Yield | -103.23% | -27.52% | |||
| FCF Yield | -86.14% | -24.44% | |||
| Buyback Yield / Dilution | -235.77% | -1,042.87% | 77.99% | -36.56% |